Research paper| Volume 31, ISSUE 4, P429-433, December 1978

One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia

      This paper is only available as a PDF. To read, Please Download here.


      The effect of bezafibrate (2-{4-[2-(4-chlorobenzamido)-ethyl]-phenoxy}-2-methylpropionic acid) (450 mg daily) on serum lipoprotein concentrations was studied for 1 year in 14 subjects with hyperlipoproteinaemia (3 of type II A, 2 of type II B, 2 of type III and 7 of type IV). After 2 months serum cholesterol decreased from 7.12−6.08 mmoles/l (15%, P < 0.01), triglycerides from 2.52−1.96 mmoles/1 (22%, P < 0.01), very low density lipoprotein triglycerides from 1.48−0.86 mmoles/1 (42%, P < 0.01) and low density lipoprotein cholesterol from 5.00−3.81 mmoles/1 (24%, P < 0.01). While triglyceride concentrations of serum and lipoproteins remained constant for 1 year, serum and LDL cholesterol concentrations increased slightly after 6 and 12 months. The former rise was partly due also to a rise of the possibly beneficial high density lipoprotein cholesterol from 1.27−1.68 mmoles/1 (32%, P < 0.01) after 6 months, making the effect on total cholesterol less pronounced.
      Subjective side-effects were nausea in one patient. No severe biochemical side-effects were noted.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Olsson A.G.
        • Rössner S.
        • Walldius G.
        • Carlson L.A.
        • Lang P.D.
        Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia.
        Atherosclerosis. 1977; 27: 279-287
        • Olsson A.G.
        • Lang P.D.
        Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
        Atherosclerosis. 1978; 31: 421
      1. Wallmüller, A., Adam, O., Wolfram, C. and Zöllner, N., Dosiswirkungsbeziehung von Bezafibrat bei Patienten mit Hypercholesterinämie and Hypertriglyceridämie, In preparation.

        • Kaffarnik H.
        • Schneider J.
        • Schubotz R.
        • Mühlfellner O.
        • Mühlfellner G.
        • Hausmann L.
        • Zöfel P.
        Long-term results with bezafibrate, a new derivate of clofibrate.
        in: Carlson L.A. Paoletti R. Weber G. International Conference on Atherosclerosis, Milan, November 1977 Raven Press, New York, NY1978: 129
        • Block W.D.
        • Jarrett K.J.
        • Leoine B.
        Use of a single color reagent to improve the automated determination of serum total cholesterol.
        in: 3rd edition. Automation in Analytical Chemistry. Vol. 1. Mediad Inc, New York, NY1965: 345
        • Kessler G.
        • Lederer H.
        Fluorimetric measurements of triglycerides.
        in: 3rd edition. Automation in Analytical Chemistry. Vol. 1. Mediad Inc, New York, NY1965: 341
        • Carlson K.
        Lipoprotein fractionation.
        J. Clin. Path. 1973; 26 (Suppl. (Ass. Clin, Path.)): 32-37
        • Beaumont J.-L.
        • Carlson L.A.
        • Cooper G.R.
        • Fejfar Z.
        • Fredrickson D.S.
        • Strasser T.
        Classification of hyperlipidaemias and hyperlipoproteinaemias.
        Bull. Wld Hlth Org. 1970; 43: 891
        • Miller N.E.
        • Miller G.J.
        High density lipoprotein and atherosclerosis.
        Lancet. 1975; 1: 1033